Investor Relations


Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a current focus on the pleuromutilin class of antibiotics. Our lead product candidate, lefamulin, is being developed as the first pleuromutilin antibiotic for intravenous (IV) and oral administration in humans. We reported positive top-line efficacy and favorable tolerability data from the LEAP 1 Phase 3 trial in September 2017 for community-acquired bacterial pneumonia (CABP). Additionally, we anticipate receiving top-line results for LEAP 2 in CABP during the spring of 2018. We also plan to develop lefamulin for additional uses and are working to build a robust pipeline of anti-infective products. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

SEC Filings

Filing date Description Form Filing Group View

Report of unscheduled material events or corporate event

Current Reports

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings
View HTML EX-101.INS - EX-101.INS

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements

Investor Contacts

David Garrett
Vice President, Corporate Controller and Head of Investor Relations Nabriva Therapeutics plc